Cartesian's immune disorder therapy meets main goal in mid-stage study (updated)

Cartesian Therapeutics

02/07/2024 11:49

(Adds details in paragraphs 2 to 3)
       July 2 (Reuters) - Cartesian Therapeutics  RNAC.O  said
on Tuesday that its experimental immune disorder therapy met the
main goal in a mid-stage trial.
    The therapy known as descartes-08 is a chimeric antigen
receptor T-cell therapy, or CAR-T cell therapy, to treat
patients with myasthenia gravis an autoimmune disorder that
causes disabling muscle weakness and fatigue.
    The company said 71% of patients in the study showed
significant improvement in symptoms as measured on a disease
severity scale at three months, compared to 25% of patients who
were given a placebo. 

 (Reporting by Sneha S K in Bengaluru; Editing by Shailesh
Kuber)
 ((Sneha.SK@thomsonreuters.com;))